Publications

European journal of cancer (Oxford, England : 1990)

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

01-02-2017

Cancer immunology research

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

01-02-2017

Oncoimmunology

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

27-01-2017

Journal of the National Cancer Institute

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

01-01-2017

Journal of clinical pharmacology

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

01-01-2017

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Oncology

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

22-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Oncoimmunology

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

01-08-2016

Journal of translational medicine

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

25-07-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

BMC cancer

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

11-06-2016

European journal of immunology

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.

01-06-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Urologic oncology

Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

The Prostate

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

01-01-2016

Journal of immunology (Baltimore, Md. : 1950)

Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization.

01-12-2015

Molecular oncology

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

01-12-2015

Clinical cancer research : an official journal of the American Association for Cancer Research

Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

01-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

Ophthalmology

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

Lancet (London, England)

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

01-08-2015

Nature reviews. Cancer

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

01-08-2015

The New England journal of medicine

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

02-07-2015

Gene therapy

Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

01-07-2015

British journal of cancer

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

30-06-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

Journal of translational medicine

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.

27-01-2015

Nature medicine

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science (New York, N.Y.)

T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert.

03-10-2014

Human gene therapy methods

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

01-10-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Molecular oncology

Acquired and intrinsic resistance in cancer immunotherapy.

12-09-2014

Cancer immunology research

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

01-06-2014

British journal of cancer

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

13-05-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Methods in molecular biology (Clifton, N.J.)

Intradermal vaccination by DNA tattooing.

10-04-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

01-03-2014

World journal of urology

Do targeted agents offer clinical benefit as presurgical therapy?

01-02-2014

BMC cancer

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

01-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

10-11-2013

Nature medicine

High-throughput identification of antigen-specific TCRs by TCR gene capture.

01-11-2013